Clinical trials · California
Systemic Sclerosis clinical trials in California
We’re tracking 22 recruiting systemic sclerosis studies with a site in California — including Early Phase 1, Phase 1, Phase 1/Phase 2, Phase 2, Phase 2/Phase 3 and Phase 3 studies, each written for real people, not researchers.
Recruiting studies in California
- NCT07497087RecruitingPhase 3
Study of nerandomilast for people with systemic sclerosis
This trial tests if nerandomilast can help people with systemic sclerosis, a disease that can affect the skin and lungs. It may be an option for those with active disease and reduced lung function.
Los Angeles, CaliforniaAges 18 years+ - NCT06655155RecruitingPhase 2
Testing efgartigimod for systemic sclerosis
This trial tests an investigational drug called efgartigimod in people with systemic sclerosis (scleroderma). The goal is to see if it can safely reduce skin thickening and improve overall health. You might qualify if your skin is moderately affected and you have certain antibodies in your blood.
Los Angeles, CaliforniaAges 18 years+ - NCT06925542RecruitingPhase 1
Study of CTX112 for adults with autoimmune disease
This trial tests an experimental cell therapy called CTX112 for people with lupus, scleroderma, or inflammatory myositis that hasn't responded well to standard treatments. The goal is to see if it's safe and if it can help control the disease.
La Jolla, CaliforniaAges 18–70 - NCT05878717RecruitingPhase 2/Phase 3
Belimumab for adults with scleroderma lung scarring
This Phase 2/3 study tests whether belimumab can improve outcomes and safety in adults with systemic sclerosis (scleroderma) that has caused lung scarring. It may help by reducing active or worsening immune-driven disease in the lungs.
Upland, CaliforniaAges 18 years+ - NCT06470048RecruitingPhase 2
Testing Ianalumab for Diffuse Cutaneous Systemic Sclerosis
This trial tests a new drug called ianalumab for people with diffuse cutaneous systemic sclerosis (a type of scleroderma affecting the skin and internal organs). It aims to see if the drug can help control the disease activity and reduce skin thickening.
Los Angeles, CaliforniaAges 18–70 - NCT07287670RecruitingPhase 2
Testing MTX-474 for diffuse scleroderma
This trial tests an investigational drug called MTX-474 for people with diffuse cutaneous systemic sclerosis (a type of scleroderma that affects the skin and internal organs). The study aims to see if it can help slow or improve skin thickening and other symptoms.
La Jolla, CaliforniaAges 18 years+ - NCT04380831RecruitingEarly Phase 1
Whole-body radiation plus chemo before stem cell transplant
This early-stage trial studies whether giving whole-body radiation and a chemotherapy medicine before an autologous stem cell transplant can improve severe systemic sclerosis. It aims to reset the immune system, but it requires careful safety checks and close follow-up.
Duarte, CaliforniaAges 18–65 - NCT06308978RecruitingPhase 1
Study of FT819 for B-cell autoimmune diseases
This trial tests a new cell therapy, FT819, for people with certain autoimmune diseases like lupus, vasculitis, myositis, or scleroderma that haven't improved with at least two previous treatments. The goal is to see if it can help control the disease.
Beverly Hills, CaliforniaAges 12–70 - NCT06375993Enrolling by invitationPhase 1
Prula-cel for autoimmune diseases: a phase 1 study
This trial tests a new treatment called prulacabtagene leucel (prula-cel), which is a type of immune cell therapy (CAR T-cells) for people with certain autoimmune diseases. It aims to see if it can reset the immune system and reduce disease activity in conditions like lupus, scleroderma, vasculitis, or myositis.
Redwood City, CaliforniaAges 18–80 - NCT07038447Enrolling by invitationPhase 1
KITE-363 for refractory autoimmune diseases
This trial tests a new cell therapy called KITE-363 for people with certain autoimmune diseases (lupus, lupus nephritis, systemic sclerosis, or idiopathic inflammatory myopathy) that haven't improved with standard treatments. It aims to see if this therapy can help control the disease.
Stanford, CaliforniaAges 18 years+ - NCT07085104RecruitingPhase 1
Study of ALLO-329 for lupus, myositis, or scleroderma
This trial tests a new one-time cell therapy (ALLO-329) made from donor cells to target and calm overactive immune cells in people with lupus, myositis, or scleroderma that hasn't improved with usual medications. It aims to see if this treatment is safe and can help reduce disease activity.
Loma Linda, CaliforniaAges 18–74 - NCT07295847RecruitingPhase 1
Study of AZD0120 for autoimmune diseases
This trial tests if a new medication, AZD0120, is safe for people with autoimmune diseases. It aims to help patients by targeting the immune system.
Stanford, CaliforniaAges 18–75 - NCT05892614RecruitingPhase 2
Efzofitimod for early systemic sclerosis lung scarring
This trial tests efzofitimod to see if it can improve or slow lung disease caused by systemic sclerosis (scleroderma), and to check safety and side effects. It focuses on people with relatively early disease and measurable lung involvement on lung scans.
Los Angeles, CaliforniaAges 18 years+ - NCT06655896RecruitingPhase 2
Rapcabtagene Autoleucel for severe diffuse scleroderma
This trial tests an investigational cell therapy called rapcabtagene autoleucel for people with severe diffuse cutaneous systemic sclerosis (a type of scleroderma that affects the skin and internal organs). The treatment uses your own modified immune cells to potentially calm the disease activity.
Los Angeles, CaliforniaAges 18–70 - NCT06733935RecruitingPhase 1/Phase 2
Study of NKX019 for immune diseases
This trial tests an investigational cell therapy called NKX019 for people with certain autoimmune diseases like scleroderma, myositis, vasculitis, or rheumatoid arthritis. It aims to see if NKX019 can help control the disease when standard treatments have not worked well enough.
Orange, CaliforniaAges 18–75 - NCT06991114RecruitingPhase 2
AlloNK and rituximab for relapsing rheumatologic diseases
This trial tests a new natural killer (NK) cell therapy called AlloNK given with rituximab for people with certain autoimmune diseases (rheumatoid arthritis, Sjögren's disease, inflammatory myopathies, or systemic sclerosis) that have not responded well to standard treatments. The goal is to see if this combination can better control the disease.
Chula Vista, CaliforniaAges 18 years+ - NCT03816345RecruitingPhase 1
Nivolumab for advanced cancer with autoimmune conditions
This Phase 1 study tests nivolumab, an immunotherapy “anti-cancer accelerator,” in people with advanced cancer who also have an autoimmune disorder. It aims to see if nivolumab can be given safely and whether it may help shrink or control cancer.
Palo Alto, CaliforniaAges 18 years+ - NCT05724173Recruiting
Test of a brain-to-computer device for ALS hand paralysis
This study checks whether a brain-computer interface (a BrainGate2 system) is safe and workable for people with ALS. If you qualify, you may be asked to try the device and complete study tasks to help researchers learn how well it can support communication or control.
Stanford, CaliforniaAges 18–80 - NCT00912041Recruiting
Test of a brain-to-computer device for quadriplegia
This study tests whether a tiny brain computer interface can help people with quadriplegia (loss of movement in all four limbs) communicate or control technology. It’s mainly a feasibility study, meaning the goal is to see if the device can work safely and reliably in real life.
Stanford, CaliforniaAges 18–80 - NCT06796504Recruiting
Device study to help repair nerve coating in RRMS
This pilot study tests a device (the SetPoint System) that may help repair the protective coating around nerves in people with relapsing-remitting MS. It focuses on participants with a specific vision test delay and stable disease activity, and aims to see if the treatment can promote remyelination.
Irvine, CaliforniaAges 22–50 - NCT06094205Recruiting
BrainGate2 speech study for people with tetraplegia
This study tests a brain-computer interface to help people with severe paralysis communicate by decoding attempted speech or movements. It may offer a new way to interact with devices using only brain signals.
Sacramento, CaliforniaAges 18–80 - NCT07468877Recruiting
Comparing two cataract surgery systems for bilateral cataract removal
This trial compares two machines used during cataract surgery to see which one uses less energy and ultrasound time. If you are healthy and need cataract surgery in both eyes, this study might help determine the best approach.
Los Angeles, CaliforniaAges 18 years+
Systemic Sclerosis trials by city in California
Where these studies are running in California
Institutions with a site for the recruiting systemic sclerosis studies listed above.
- Stanford University · 6 studies
- University of California, Los Angeles (UCLA) · 4 studies
- City of Hope Comprehensive Cancer Center · 2 studies
- University of California, Davis Medical Center · 2 studies
- Adicet Clinical Trials
- Advanced Vision Care
- Artiva Investigational Site Chula Vista
- Artiva Investigational Site Covina
What taking part in a systemic sclerosis study involves
A screening visit first
Before anything else, the study team checks whether you fit — usually a visit with some tests. You can stop at any point, and screening is typically free.
Care at a nearby site
Study visits happen at a clinic or hospital taking part. Many studies cover the cost of the study treatment and related visits, and some reimburse travel.
You stay in control
Taking part is voluntary and you can leave a study at any time, for any reason, without affecting your regular care.
The team decides eligibility
Our fit check is a helpful first read, not a decision. The study team makes the final call after reviewing your health history.
Systemic Sclerosis trials in other states
Common questions
- Are there systemic sclerosis clinical trials in California?
- Yes. We're currently tracking 22 recruiting systemic sclerosis studies with a site in California, each rewritten in plain language so you can see what it's testing and who it's for.
- How do I find out if I qualify for a systemic sclerosis study in California?
- Each study lists its eligibility rules — age, diagnosis, prior treatments. On every trial page we explain these in plain language and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Do I have to live in California to take part?
- Not necessarily. These studies have a site in California, but eligibility is about your health, not your address — some people travel to take part, and a few studies reimburse travel. The study team can tell you what's required.
- Does it cost anything to join a systemic sclerosis trial?
- Using Clin2 is always free. Many trials cover the study treatment and related visits; some reimburse travel. The study team explains exactly what's covered before you decide.
Not the right time?
New systemic sclerosis studies open in California regularly. Set up a health profile and we’ll quietly watch for studies that fit you and email you when one opens.
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.